Edgar Filing: ELITE PHARMACEUTICALS INC /NV/ - Form 4

ELITE PHARMACEUTICALS INC /NV/

Form 4 June 18, 2014

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

Washington, D.C. 20549

January 31, Expires: 2005

Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Estimated average burden hours per response... 0.5

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * TREPPEL JERRY

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Symbol

ELITE PHARMACEUTICALS INC

(Check all applicable)

/NV/ [ELTP]

(Last) (First) 3. Date of Earliest Transaction

X Director 10% Owner

(Middle)

(Month/Day/Year) 06/17/2014

Filed(Month/Day/Year)

3.

Code

X_ Officer (give title Other (specify below)

Chairman of the Board

C/O WHEATON CAPITAL MANAGEMENT LLC, 13

LUCILLE CT.

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Issuer

X Form filed by One Reporting Person

Form filed by More than One Reporting

EDISON, NJ 08820

1.Title of

(City)

Security

(Instr. 3)

(State)

(Month/Day/Year)

(Street)

(Zip)

Execution Date, if

(Month/Day/Year)

2. Transaction Date 2A. Deemed

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

4. Securities Acquired

(Instr. 3, 4 and 5)

5. Amount of

7. Nature of Ownership Indirect Form: Direct Beneficial

(Instr. 8)

Transaction(A) or Disposed of (D)

Owned Following Reported

Securities

Beneficially

(D) or Ownership Indirect (I) (Instr. 4)

(9-02)

(Instr. 4)

(A)

Transaction(s)

Code V

(D) Price Amount

(Instr. 3 and 4)

Stock

Common

06/17/2014

 \mathbf{C} 375,000 3,206,558

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: ELITE PHARMACEUTICALS INC /NV/ - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Warrants	\$ 0.25	06/17/2014		C		375,000	06/30/2009	06/30/2014	Common Stock	375,00

Reporting Owners

Reporting Owner Name / Address		Relationships						
reporting owner runte, runtess	Director	10% Owner	Officer	Other				
TREPPEL JERRY								
C/O WHEATON CAPITAL MANAGEMENT LLC			Chairman of the Board					
13 LUCILLE CT.	X		Chairman of the Board					
EDISON, NJ 08820								

Signatures

Jerry Treppel 06/18/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2